5 billion in 2001 and developer of FluMist

BERKELEY, Calif., Jan 5, 2009 (GLOBE NEWSWIRE) XOMA, Ltd. Kurland will beresponsible for directing XOMA's financial strategy, accounting, financialplanning and investor relations functions."Fred is a seasoned financial executive with over 30 years of experience inbiotechnology and pharmaceutical companies including Aviron/MedImmune, ProteinDesign Labs and Syntex/Roche," noted Steve Engle, Chairman and CEO of XOMA. "Hewill be a very valuable addition to XOMA's executive team, particularly as ouranti-IL-1 beta blocker XOMA 052 advances into Phase 2 trials."Prior to joining XOMA, Mr. Kurland served as CFO of Bayhill Therapeutics, Inc.,Corcept Therapeutics Incorporated and Genitope Corporation From 1998 to 2002,Mr. Kurland served as Senior Vice President and CFO of Aviron, acquired byMedImmune for $1.5 billion in 2001 and developer of FluMist. From 1996 to 1998,he was Vice President and CFO of Protein Design Labs, Inc., an antibody designcompany, and from 1995 to 1996, he served as Vice President and CFO of AppliedImmune Sciences, Inc.Mr.

Kurland held a number of financial management positions at SyntexCorporation, a $2.1 billion pharmaceutical company acquired for $5.3 billion byRoche, including Vice President and Controller between 1991 and 1995 Hereceived his J.D and M.B.A. degrees from the University of Chicago and his B.S.degree from Lehigh University.About XOMAXOMA discovers, develops and manufactures therapeutic antibody and other agentsdesigned to treat inflammatory, autoimmune, infectious and cancerous diseases.The company's proprietary product pipeline includes XOMA 052, an anti-IL-1 betaantibody, and XOMA 3AB, a biodefense anti-botulism antibody candidate.XOMA's proprietary development pipeline is primarily funded by multiple revenuestreams resulting from the licensing of its antibody technologies, productroyalties, development collaborations and biodefense contracts. XOMA'stechnologies and experienced team have contributed to the success of marketedantibody products, including RAPTIVA(r) (efalizumab) for chronic moderate tosevere plaque psoriasis, LUCENTIS(r) (ranibizumab injection) for wet age-relatedmacular degeneration and CIMZIA(r) (certolizumab pegol) for Crohn's disease.The company has a premier antibody discovery and development platform thatincorporates leading antibody phage display libraries and XOMA's proprietaryHuman Engineering(tm) and bacterial cell expression and manufacturingtechnologies. Bacterial cell expression (BCE) is a key breakthroughbiotechnology for the discovery and manufacturing of antibodies and otherproteins.

As a result, more than 50 pharmaceutical and biotechnology companieshave signed BCE licenses.In addition to developing its own products, XOMA develops products with premierpharmaceutical companies including Novartis AG, Schering-Plough ResearchInstitute and Takeda Pharmaceutical Company Limited. XOMA has a fully integratedproduct development infrastructure, extending from pre-clinical science toapproval, and a team of 335 employees at its Berkeley location. For moreinformation, please visit http:// statements contained herein relating to product development, or thatotherwise relate to future periods, are forward-looking statements within themeaning of Section 27A of the Securities Act of 1933 and Section 21E of theSecurities Exchange Act of 1934. These statements are based on assumptions thatmay not prove accurate. Consider such risks carefully in considering XOMA's prospects.-0-CONTACT:Porter Novelli Life Sciences for XOMAMedia & Investors Contact:Carolyn .

Kirchner Appointed CEO; Joins Company FromUPS Supply Chain Solutions Roger I. MacFarlane to Become Non-Executive ChairmanLONG BEACH, Calif., Jan. 5, 2009 (GLOBE NEWSWIRE) UTi Worldwide (Nasdaq:UTIW)today announced that it has appointed Eric W. Kirchner as chief executiveofficer, with an effective date expected on or about January 19, 2009.